In a study published today in the open-access journal The Lancet Global Health, the Drugs for Neglected Diseases initiative (DNDi) and other researchers report a persistent deficiency in truly new therapeutics for neglected diseases, despite nominal progress and an acceleration in research and development (R&D) efforts. |
This continued ‘fatal imbalance’ in medical R&D points to the urgent need to develop and deliver groundbreaking new treatments for the world’s poorest and most neglected patients. MY TAKE: If Cancer, Heart Disease, Diabetes and 93 other autoimmune diseases qualify as “neglected diseases,” then we are absolutely at a roadblock in American medicine. This article says despite progress, we just haven’t made enough new drugs! {flike} |